Disclosure of payments made to HCPs and HCOs in the UK
ALK-Abelló Ltd is committed to greater transparency of financial relationships with healthcare professionals and healthcare organisations. Alongside other ABPI member companies, ALK-Abelló Ltd discloses all transfers of value made to healthcare professionals and healthcare organisations. This is in line with the ABPI Code of Practice as well as the EFPIA Disclosure Code, which has been adopted across 33 European countries. This disclosure is made annually on the ABPI website, Disclosure UK.
Our payments made to HCPs and HCOs in the UK in 2021
In 2021 ALK-Abelló Ltd paid a total of £36,719.85 to support 46 UK HCP’s to attend scientific conferences and meetings, to speak at ALK-Abelló meetings and to provide various consultancy services. Disclosure at an individual level is voluntary. Where consent has not been obtained to disclose on a named basis the total amount is shown in aggregate.
In addition to the transfers of value stated above, £17,666 was paid to HCPs and HCOs for costs directly associated with research and development.
ALK-Abelló Ltd also paid a total of £48,425 to HCO’s in sponsorships and grants, details of individual payments to HCO’s can be also be found in the link above.
Financial Support Given to Patient Organisations and Charities
Payments made to patient organisations and charities are not detailed as part of the ABPI disclosure process. In the interest of total transparency payments made to these organisations are listed below.
Over the past 3 years ALK UK Ltd has given financial support to the following patient organisations & charities:
2020
Anaphylaxis Campaign £39,190
Educational support to help raise awareness of the signs, symptoms and treatment options for patients at risk of anaphylaxis.
Allergy UK £38,500
Educational support to help raise awareness of the signs, symptoms and treatment options for patients with allergic disease and patients at risk of anaphylaxis.
2021
Allergy Research Ltd (ARL) - a subsidiary of the charity British Allergy Foundation £72,502
Support to aid further research into the development of treatments for patients with asthma
Anaphylaxis Campaign £28,940
Educational support to help raise awareness of the signs, symptoms and treatment options for patients at risk of anaphylaxis.
Asthma Society of Ireland €18,000
Educational support to help raise awareness of the signs, symptoms and treatment options for patients with asthma, allergic disease and patients at risk of anaphylaxis.
2022
In 2022 ALK-Abelló Ltd paid a total of £24133.37 to support 52 UK HCP’s to attend scientific conferences and meetings, to speak at ALK-Abelló meetings and to provide various consultancy services. Disclosure at an individual level is voluntary. Where consent has not been obtained to disclose on a named basis the total amount is shown in aggregate.
ALK-Abelló Ltd also paid a total of £50890 to HCO’s in sponsorships and grants, details of individual payments to HCO’s can be also be found in the link above.
| Project Title | Allergy Pathway optimisation project |
| Partner organisation/s |
ALK, NHS trusts:
The project will be delivered on behalf of ALK by IQVIA Technology services Ltd |
| Project Rational |
The management of allergy patients across primary and specialised care is not uniformly implemented. There is variation in diagnostic and treatment practice across the UK. Evidence of clinical practice suggests that patients with severe allergy often undergo tests that do not support their disease needs prior to an allergy specialist referral, and patients that could benefit from innovative disease modifying treatments such as allergen immunotherapy wait excess time until the right technology is prescribed to them.
|
| Project Period | Commencing Q4 2022 |
| Project Objectives/Overview |
Review the Allergy Pathway at NHS Trust level (3 paediatric services and 3 adult services): to map the existing patient pathway, identify immediate opportunities to improve the current pathway. Identify barriers to further optimization of the pathway and understand potential solutions to overcome those barriers.
Key themes identified within the individual allergy services, will be discussed with members of a steering committee comprising of representatives of partner NHS trusts and relevant national allergy stakeholders.
|
| Expected Benefits to patients/Patient/NHS and ALK |
Patients – improved access potential to allergy services and treatments (ii) Trust – full utilisation of current allergy expertise and capacity, increased patient numbers and simplified operational processes, prioritised action plan to deliver further pathway improvements. (iii) ALK – opportunity to work with allergy service providers to learn and understand current pathway challenges and support potential pathway improvement opportunities to improve their services. |
2023
In 2023 ALK-Abelló Ltd paid a total of £67,328.29 to support 92 UK HCP’s to attend scientific conferences and meetings, to speak at ALK-Abelló meetings and to provide various consultancy services. Disclosure at an individual level is voluntary. Where consent has not been obtained to disclose on a named basis the total amount is shown in aggregate.
ALK-Abelló Ltd also paid a total of £39,578.00 to HCO’s in sponsorships and grants, details of individual payments to HCO’s can be also be found in the link above.
IE-NPR-2400008 October 2024